Exciting new drugs on the horizon - Eplerenone, a selective aldosterone receptor antagonist (SARA)

International Journal of Cardiology

Volumn 80, Issue 1, 2001, Pages 1-4

  Coats, A J S ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Aldosterone; Eplerenone; Heart failure; Hyperaldosteronism; Hypertension; Randomised controlled trial; Selective Aldosterone Receptor Antagonist; Spironolactone; Survival

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; NEUROHORMONE; PLACEBO; SPIRONOLACTONE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEATH; DRUG ANTAGONISM; DRUG SELECTIVITY; FOLLOW UP; GYNECOMASTIA; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; KIDNEY DISEASE; MENSTRUAL IRREGULARITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0034866680     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(01)00516-2     Document Type: Editorial

References (27)

1. Cardiovascular research in the dock: A case for the defence
2. The importance and complexity of neurohumeral over-activity in chronic heart failure
3. Angiotensin receptor blockers - Finally the evidence is coming in: IDNT and RENAAL
4. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
5. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease
6. CURE - Clopidogrel's major advance
7. The effects of angiotensin receptor antagonists on mortality and morbidity in heart failure - And an interaction with beta blockade
8. The effect of adrenal hormones on the circulation
9. Hormonal regulation of cardiac fibroblast function
10. Aldosterone: A mediator of myocardial necrosis and renal arteriopathy
11. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy
12. Prognostic value of left ventricular hypertrophy and geometry in patients with a first, uncomplicated myocardial infarction
13. Intraventricular conduction delay: A prognostic marker in chronic heart failure
14. Left ventricular remodelling: Common process in patients with different primary myocardial disorders
15. Left ventricular remodelling and dysfunction. Can the process be prevented?
16. National service framework heart failure
17. The effects of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status in patients with heart failure
18. Disagreement between drug effects on autonomic function and mortality: Another unreliable surrogate endpoint in heart failure?
19. Heart failure 99 - The MOXCON story
20. Will aldosterone blockade in acute myocardial infarction be useful?
21. Beta-blockers - Again, a lesson to us all, especially the research funding community
22. The combination ace-inhibitors plus canreonate in patients with anterior myocardial infarction: Safety and tolerability study
23. Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology
24. The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure
25. Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension
26. Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications
27. The EPHESUS Trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction